Amgen ( NASDAQ: AMGN ) recently announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS ® (sotorasib) (960 mg or 240 mg) in combination with Vectibix ® (panitumumab). Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). The results are being presented today at the Presidential Symposium 2 session as a late-breaking oral presentation (LBA10) during the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, with simultaneous publication in the New England Journal of Medicine.